Ideas·Trials & Triumphs
The thinking behind the build.
Field notes on the work that actually happens between RFI and First Patient In, from the team building the infrastructure for it.
Presentation · October 2026
106 days from Brussels
The impact of the EU-CTR on the European clinical trial market: what the public register shows about authorisation timelines, Europe’s share of trials and the value at stake.
Access the presentation
Latest essay
Selling Uncertainty: The Business of Clinical Trials
How the absence of agreed-upon execution standards breeds the price war and erodes CRO margins.
Read the essayWhy CROs Lose Bids They Should Win
You and your five competitors ran the same race, on the same clock. The sponsor picked the cheapest and moved on. Completeness is not persuasion.
Read the essaySite Engagement Without Site-Facing Tech: How We Got Here
We scaled a site-facing marketplace to 1,400 sites in three months, then killed it. The story of why portals are the wrong model, and what we built instead.
Read the essayWhy Pharma and Biotech Struggle to Choose the Right CRO
Capability is a corporate fact. Delivery is what these specific people do for this specific protocol when the plan breaks.
Read the essayWhy We Decided To Build For CROs First
We bet on the infrastructure that runs clinical trials today and will still run them tomorrow.
Read the essayIs Single Sign-On Really What Sites Need?
We let the complaint dictate what we build. But SSO is a falsche Fährte, a false trail. The real problem is somewhere else.
Read the essayPlatform Trials as a Service: A CRO Model for Rare Diseases?
Clinical trials today are still prototypes. Ford’s revolution wasn’t the car. It was the assembly line.
Read the essayThe Whitespace Tax: Why Biotechs Lose Time, Money, and Patients Before First-Patient-In
The silence between “site selected” and “site activated” costs about $80,000 a day, and sometimes a patient’s last good option.
Read the essayWhy Drug Development Slowed Down (And What Can Be Done)
Drugs once reached patients in months. A journey back to the era before regulation tightened its grip.
Read the essayA Theory of Site Engagement
Sites are the atomic unit of clinical development. Yet no company has a structured view of the quality of its relationships with them.
Read the essayWhy Commercial Teams Obsess Over HCP Data, and What ClinOps Must Learn
The most valuable data isn’t in your lab notebooks. It’s in how you select, engage, and contract with your sites.
Read the essayThe newsletter
Trials & Triumphs
New essays on the work between RFI and First Patient In, direct to your inbox.
Subscribe
